Kropotova Alexandra 4

What Happened

• Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics (SABS), received a grant of 2,400,000 derivative awards on 2026-02-03. The Form 4 lists the award as 2,400,000 shares at $0.00 (standard reporting format for option grants); no cash was paid.
• The filing was submitted on 2026-02-05. The exercise/strike price and post-transaction beneficial ownership are not specified in the provided excerpt, so no immediate dollar value can be calculated from this filing alone.

Key Details

• Transaction date: 2026-02-03; Form 4 filed: 2026-02-05 (appears within the common 2-business-day reporting window).
• Transaction type: Award/Grant (derivative option grant) — 2,400,000 options shown at $0.00 on the filing.
• Plan: Issued under the Issuer’s 2021 Omnibus Equity Incentive Plan (footnote F1).
• Vesting: 1/4 vests on the one-year anniversary of the grant; remaining 3/4 vests pro rata monthly over the following 36 months (footnote F2).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• No immediate sale or cashless exercise reported — this is a time-vesting equity award, not a sale.

Context

• These are option awards (the right to purchase shares in the future subject to vesting and exercise terms). Such grants are commonly used for executive compensation and retention and do not by themselves indicate immediate buying or selling of stock.
• Because the exercise price and current ownership aren’t shown here, retail investors should not infer a dollar value or a definitive insider sentiment from this single grant.